arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Indivior Pharmaceuticals, Inc.

INDV Health Care Biotechnology: Pharmaceutical Preparations
$35.33
▲ +1.6% Today
as of Oct 22, 16:49 ET
Last 30 days +2.49% Sep 14 → Oct 22
$32.10 $33.38 $34.67 $35.95 $37.23 Sep 14 Sep 22 Sep 29 Oct 07 Oct 14 Oct 22
Open
$34.77
High
$35.36
Low
$34.54
Volume
$871,670
Avg Vol
$2M
Mkt Cap
$4.3B
P/E (TTM)
16.23
Beta
—
52w High
$42.81
52w Low
$24.28
Div Yield
—
Shares Out
—

Recent Press Releases & News last 60 days · 5 items

Oct 19 · 12:30 PR GlobeNewswire
Indivior to Report Third Quarter 2026 Financial Results
Sep 17 · 11:00 PR GlobeNewswire
Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend
Sep 2 · 15:30 Zacks
Indivior Pharmaceuticals Inc. (INDV) Down 5.3% Since Last Earnings Report: Can It Rebound?
▸ Show all 5 press releases & news Free account →

INDV earnings at a glance

Indivior Pharmaceuticals, Inc. (INDV) is scheduled to report earnings on Thursday, October 29, 2026 — in 6 days. Analysts expect earnings per share of $0.93, compared with $0.72 in the same quarter last year (+29%). The options market is pricing a move of about ±13.7% after the report, a range of roughly $30.50 to $40.16 from today's $35.33. Over its last 6 reports the stock rose the next day 5 times and fell 1, moving ±10.0% on average; after the most recent report on Aug 4, 2026 it moved -6.6%. That means options currently expect more movement than INDV has typically delivered. INDV beat the consensus EPS estimate in 6 of its last 6 reported quarters. Implied volatility is currently 116%. The share price of $35.33 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$24
$43
60% of range
Avg surprise (last 6)
+61.1%
Avg reaction (last 6)
+7.8%
83% positive
Latest IV / EM
116%
EM ±13.7% · $35 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.72$-0.25$0.21$0.68$1.15 Actual $0.45Actual $-0.72Actual $0.16Actual $0.41Est $0.22Actual $0.51Est $0.26Actual $0.72Est $0.38Actual $0.82Est $0.65Actual $0.96Est $0.64Actual $1.15Est $0.97 MarJunSepMar/2025Jun/2025Sep/20258K8KJun/2026
Revenue vs Net Income Revenue Net income
$0$90M$180M$270M$360M Sep 24Dec 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Aug 4, 2026Jun/2026 $1.15 $0.97 +18.6% +90.2% -6.6% earnings
Thu Apr 30, 20268K 2026-04-30 $0.96 $0.64 +50.0% — +7.7% earnings
Thu Feb 26, 20268K 2026-02-26 $0.82 $0.65 +26.1% — +0.2% earnings
Thu Oct 30, 2025Sep/2025 $0.72 $0.38 +89.5% — +15.4% earnings
Thu Jul 31, 2025Jun/2025 $0.51 $0.26 +96.2% — +16.1% earnings
Thu Apr 24, 2025Mar/2025 $0.41 $0.22 +86.4% — +13.9% earnings
Mon Sep 30, 2024Sep 2024 $0.16 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.72 — — — — financials
Sun Mar 31, 2024Mar 2024 $0.45 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Thu Oct 29, 2026Sep/2026OTHER $0.93$0.72 +29.2%

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$343M$317M—$314M$302M$266M—$307M
Cost of revenue$50M$40M—$83M$52M$44M—$66M
Gross profit$294M$277M—$230M$250M$221M—$241M
Operating income$160M$137M—$43M$72M$66M$46M—
Net income$122M$89M—$42M$18M$47M$21M—
EPS (diluted)$0.98$0.69—$0.33$0.14$0.38—$0.16

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$222M$175M$195M$445M$510M$372M$319M—
Inventory$150M$152M$153M$155M$149M$163M$167M—
Total current assets$725M$667M$652M$922M$951M$883M$827M—
Total assets$1.23B$1.20B$1.20B$1.42B$1.45B$1.38B$1.32B—
Long-term debt$487M$486M$290M$304M$308M$311M$315M—
Total liabilities$1.44B$1.34B$1.30B$1.62B$1.71B$1.66B$1.65B—
Total equity$-208M$-144M$-98M$-207M$-257M$-285M$-337M$-310M

Implied volatility — last 90 days

37%72%106%141%176% Jun 07 — IV 71% · EM ±9.9%Jun 08 — IV 64% · EM ±8.4%Jun 09 — IV 81% · EM ±10.1%Jun 11 — IV 85% · EM ±9.4%Jun 12 — IV 88% · EM ±9.0%Jun 15 — IV 72% · EM ±5.2%Jun 16 — IV 100% · EM ±5.9%Jun 17 — IV 177% · EM ±7.4%Jun 19 — IV 42% · EM ±9.3%Jun 22 — IV 53% · EM ±11.0%Jun 23 — IV 56% · EM ±11.4%Jun 24 — IV 59% · EM ±11.8%Jun 25 — IV 53% · EM ±10.3%Jun 26 — IV 51% · EM ±9.7%Jun 29 — IV 52% · EM ±9.1%Jun 30 — IV 61% · EM ±10.5%Jul 01 — IV 47% · EM ±7.9%Jul 02 — IV 59% · EM ±9.6%Jul 03 — IV 61% · EM ±9.5%Jul 06 — IV 57% · EM ±7.9%Jul 07 — IV 82% · EM ±10.8%Jul 08 — IV 37% · EM ±4.6%Jul 09 — IV 73% · EM ±8.6%Jul 10 — IV 64% · EM ±7.0%Jul 13 — IV 57% · EM ±4.7%Jul 14 — IV 135% · EM ±9.7%Jul 15 — IV 80% · EM ±4.7%Jul 16 — IV 94% · EM ±3.9%Jul 20 — IV 68% · EM ±16.0%Jul 21 — IV 55% · EM ±12.9%Jul 22 — IV 58% · EM ±13.2%Jul 23 — IV 60% · EM ±13.5%Jul 24 — IV 63% · EM ±13.9%Jul 27 — IV 64% · EM ±13.4%Jul 28 — IV 72% · EM ±14.8%Jul 29 — IV 68% · EM ±13.7%Jul 30 — IV 68% · EM ±13.4%Jul 31 — IV 75% · EM ±14.3%Aug 03 — IV 83% · EM ±14.7%Aug 04 — IV 68% · EM ±11.8%Aug 05 — IV 64% · EM ±10.7%Aug 06 — IV 50% · EM ±8.1%Aug 07 — IV 57% · EM ±8.9%Aug 12 — IV 71% · EM ±8.9%Aug 14 — IV 75% · EM ±8.3%Aug 17 — IV 103% · EM ±8.6%Aug 24 — IV 57% · EM ±12.0%Aug 25 — IV 54% · EM ±11.1%Aug 26 — IV 56% · EM ±11.2%Aug 27 — IV 39% · EM ±7.6%Aug 28 — IV 54% · EM ±10.3%Aug 31 — IV 48% · EM ±8.4%Sep 01 — IV 59% · EM ±10.1%Sep 03 — IV 56% · EM ±9.0%Sep 04 — IV 62% · EM ±9.7%Sep 07 — IV 70% · EM ±9.7%Sep 10 — IV 87% · EM ±10.2%Sep 15 — IV 95% · EM ±6.9%Sep 21 — IV 46% · EM ±9.6%Sep 22 — IV 66% · EM ±13.6%Sep 23 — IV 56% · EM ±11.3%Sep 24 — IV 54% · EM ±10.6%Sep 25 — IV 53% · EM ±10.1%Sep 28 — IV 53% · EM ±9.4%Sep 29 — IV 63% · EM ±10.8%Sep 30 — IV 63% · EM ±10.6%Oct 01 — IV 66% · EM ±10.6%Oct 02 — IV 71% · EM ±11.1%Oct 05 — IV 80% · EM ±11.1%Oct 06 — IV 77% · EM ±10.2%Oct 08 — IV 116% · EM ±13.7%

Sector peers

TLX
Telix Pharmaceuticals Limited
$3.9B $9.54-14.5%
CPRX
Catalyst Pharmaceuticals, Inc.
$3.9B $31.49
GMAB
Genmab A/S
$4.7B $40.00+2.4%
DNTH
Dianthus Therapeutics, Inc.
$4.7B $78.53-0.3%
TNGX
Tango Therapeutics, Inc.
$3.7B $27.93+10.6%
IDYA
IDEAYA Biosciences, Inc.
$3.5B $36.12+2.1%

INDV earnings FAQ

When is INDV's next earnings date?

Indivior Pharmaceuticals, Inc. is expected to report on October 29, 2026.

What is INDV's expected move for earnings?

Options currently price a move of about ±13.7%, or $4.83 per share either way from $35.33.

How does INDV stock usually react to earnings?

Across the last 6 reports the average next-day move was ±10.0%, up 5 times and down 1 times.

What EPS are analysts expecting from Indivior Pharmaceuticals, Inc. ?

The consensus estimate is $0.93 per share, versus $0.72 a year ago.

What is INDV's implied volatility?

INDV's at-the-money implied volatility is about 116% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in